Merck has received new approval from the National Medical Products Administration of China for the drug KEYTRUDA. It can now be used in combination with platinum- and fluoropyrimidine-based chemotherapy to treat patients with inoperable or metastatic esophageal or gastroesophageal transition cancer. KEYTRUDA is now approved for eight indications in five different types of cancer in China.